[Impact of Splenomegaly on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Myelomonocytic Leukemia]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2020 May 26

PMID 32447935

Citations 2

Authors

C Zhao

X J Huang

X S Zhao

Y Wang

C H Yan

L P Xu

X H Zhang

K Y Liu

Y Q Sun

Affiliations

Soon will be listed here.

Abstract

To retrospectively analyzed the impact of splenomegaly on outcomes in patients with chronic myelomonocytic leukemia (CMML) receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Clinical data of 25 patients with CMML receiving allo-HSCT at Peking University Institute of Hematology from 2004-2018 were retrospectively analyzed. Engraftment, graft versus host disease (GVHD) , relapse, survival were compared between patients with or without splenomegaly before transplantation. There were 15 splenomegaly patients including 8 males and 7 females with a median age of 45 (23-61) years, and 10 non-splenomegaly patients including 5 males and 5 females with a median age of 39 (12-56) years. Clinical characteristics at baseline were comparable in two groups (>0.05) . The neutrophil engraftment rates in splenomegaly and non-splenomegaly patients were 93.3% (14/15) and 100.0% (10/10) , and with a median time of 17 (11-20) days and 14 (11-18) days respectively ((2)=5.303, =0.021) . The platelet engraftment rates in splenomegaly and no-splenomegaly patients were 80.0% (12/15) and 90.0% (9/10) (=0.212) , and the median time of engraftment was 17 (12-33) days and 15 (12-19) days respectively ((2)=0.470, =0.493) . Five patients with splenomegaly developed acute GVHD (aGVHD) (4 patients with grade Ⅰ/Ⅱ, 1 with grade Ⅲ/Ⅳ) , and 6 patients developed aGVHD in non-splenomegaly group (5 with grade Ⅰ/Ⅱ, 1 with grade Ⅲ/Ⅳ) ((2)=0.204, =0.652) . The cumulative incidences of aGVHD at 100 days between two groups were 33.3% (95% 14.9%-51.7%) and 20.0% (95% 2.8%-37.2%) respectively (=0.635) . Five patients in splenomegaly group developed chronic GVHD (cGVHD) including 3 patients with extensive cGVHD. None in non-splenomegaly group reported cGVHD (=0.041) . The 3-year cumulative incidences of relapse in splenomegaly and non-splenomegaly patients were (42.7±2.6) % and (11.1±1.2) % (=0.122) , and the 3-year overall survival rates were (61.5±13.5) % and (68.6±15.1) % ((2)=0.351, =0.554) . In addition, the leukemia-free survival rates were (56.3±14.8) % and (80.0±17.9) % respectively ((2)=1.148, =0.284) . In CMML patients receiving allo-HSCT, splenomegaly may have an impact on the time of neutrophil engraftment, but not affecting disease relapse and survival.

Citing Articles

[Clinical outcomes of allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia].

Zhang X, Zhou J Zhonghua Xue Ye Xue Za Zhi. 2024; 45(1):18-21.

PMID: 38527833 PMC: 10951112. DOI: 10.3760/cma.j.cn121090-20231007-00160.

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders.

Symeonidis A, Chondropoulos S, Verigou E, Lazaris V, Kourakli A, Tsirigotis P Front Oncol. 2022; 12:884723.

PMID: 35992818 PMC: 9389581. DOI: 10.3389/fonc.2022.884723.

References

Sun Y, Beohou E, Labopin M, Volin L, Milpied N, Yakoub-Agha I . Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the.... Haematologica. 2016; 101(8):e352-4. PMC: 4967588. DOI: 10.3324/haematol.2015.140509. View

Xu L, Chen H, Chen J, Han M, Huang H, Lai Y . The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J Hematol Oncol. 2018; 11(1):33. PMC: 5833104. DOI: 10.1186/s13045-018-0564-x. View

Steensma D, Tefferi A, Li C . Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome. Leuk Res. 2003; 27(9):775-82. DOI: 10.1016/s0145-2126(03)00006-7. View

Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-56. DOI: 10.1016/j.bbmt.2005.09.004. View

Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R . Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clin Lymphoma Myeloma Leuk. 2016; 16(5):297-303. DOI: 10.1016/j.clml.2016.02.004. View

Robertson F, Leander P, Ekberg O . Radiology of the spleen. Eur Radiol. 2001; 11(1):80-95. DOI: 10.1007/s003300000528. View

Zhao Y, Gao F, Shi J, Luo Y, Tan Y, Lai X . Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019; 25(9):1898-1907. DOI: 10.1016/j.bbmt.2019.05.036. View

Solary E, Itzykson R . How I treat chronic myelomonocytic leukemia. Blood. 2017; 130(2):126-136. DOI: 10.1182/blood-2017-04-736421. View

Geissler K, Jager E, Barna A, Sliwa T, Knobl P, Schwarzinger I . In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia. Eur J Haematol. 2016; 97(6):562-567. DOI: 10.1111/ejh.12773. View

10.

Padron E, DeZern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q . A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clin Cancer Res. 2016; 22(15):3746-54. PMC: 5278764. DOI: 10.1158/1078-0432.CCR-15-2781. View

11.

Pozo A, Godfrey E, Bowles K . Splenomegaly: investigation, diagnosis and management. Blood Rev. 2008; 23(3):105-11. DOI: 10.1016/j.blre.2008.10.001. View

12.

Kong Y, Chang Y, Wang Y, Chen Y, Han W, Wang Y . Association of an impaired bone marrow microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 19(10):1465-73. DOI: 10.1016/j.bbmt.2013.07.014. View

13.

Alchalby H, Yunus D, Zabelina T, Ayuk F, Kroger N . Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2016; 51(9):1223-7. DOI: 10.1038/bmt.2016.98. View

14.

Rohrer C, Arni U, Deubelbeiss K . Influence of the spleen on the distribution of blood neutrophils. Quantitative studies in the rat. Scand J Haematol. 1983; 30(2):103-9. DOI: 10.1111/j.1600-0609.1983.tb01451.x. View

15.

Akahoshi Y, Kimura S, Gomyo A, Hayakawa J, Tamaki M, Harada N . Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome. Hematol Oncol. 2017; 36(1):276-284. DOI: 10.1002/hon.2427. View

16.

Shimomura Y, Hara M, Katoh D, Hashimoto H, Ishikawa T . Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol. 2018; 97(6):1049-1056. DOI: 10.1007/s00277-018-3278-9. View

17.

Hunter A, Zhang L, Padron E . Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia. Curr Treat Options Oncol. 2018; 19(12):67. DOI: 10.1007/s11864-018-0581-6. View

18.

Patnaik M, Tefferi A . Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. Am J Hematol. 2018; 93(6):824-840. PMC: 5995129. DOI: 10.1002/ajh.25104. View

19.

Przepiorka D, Weisdorf D, MARTIN P, Klingemann H, Beatty P, Hows J . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6):825-8. View

20.

Hart C, Klatt S, Barop J, Muller G, Schelker R, Holler E . Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Haematologica. 2016; 101(11):1407-1416. PMC: 5394870. DOI: 10.3324/haematol.2016.146811. View